MHRA (UK)Original article
Research: Use of UK plasma for the manufacture of five further plasma derived medicinal products and vCJD risk
RegulatoryAlbuminFibrinogenProthrombin Complex ConcentratesNeutral
AI Analysis
Summary
The MHRA completed a safety review of five plasma-derived medicinal products manufactured from UK-sourced plasma regarding vCJD risk, with results published in July 2026. This follows a previous 2023 review of albumins manufactured from UK plasma.
Outcome Details
MHRA completed safety review of five plasma-derived medicinal products manufactured from UK-sourced plasma with respect to vCJD risk
Importance:3/10
Sentiment:
0.00
regulatory_reviewplasma_derived_productsvCJD_safetyUK_sourced_plasmaMHRA
Read the original article
Published by MHRA (UK) on July 9, 2026 11:55 AM